Why Is KINIKSA PHARMACEUTIC A (KNSA) Stock Up Today?

Kiniksa Pharmaceuticals (KNSA) shares surged 22.23% to close at $89.20. The primary driver was the company’s third-quarter 2026 financial results, which featured a 58% year-over-year increase in ARCALYST revenue and a raised full-year revenue forecast.

What Happened

Kiniksa reported robust third-quarter performance, with ARCALYST sales growing 58% year-over-year. The company raised its 2026 revenue guidance to a range of $1.045 billion to $1.050 billion. Profit growth is outpacing revenue gains, providing the company with resources to advance pipeline candidates without diluting shareholders. The stock closed at a 52-week high, a level it had not previously reached.

Wedbush adjusted its price target on the stock following the release. The company also provided updates on its KPL-387 timeline, with data expected in the second half of 2027. The earnings call presentation highlighted the blockbuster prospects for the Regeneron-partnered drug.

What The Data Shows

The stock printed 19 fresh 52-week highs and two fresh 52-week lows on October 27, 2026. The 52-week range is $35.20 to $84.06, meaning the closing price of $89.20 exceeds the previous high. Over the last eight sessions, the stock moved up 13.5%, rising from $78.59 to $89.20.

Fundamentals show a market cap of $6.0 billion, a P/E ratio of 73.7, and a net margin of 9.6%. Trailing twelve-month revenue grew 58.9%. The stock has a beta of 0.04. In the last 90 days, there were no insider buys and one sale totaling $299,000. Director Cole G Bradley sold shares on July 29, 2026.

What To Watch

Investors will monitor the company’s progress on KPL-387 data, which is expected in the second half of 2027. The stock’s position above its previous 52-week high may draw further attention from analysts and traders.